(Q45398057)

14 December 2017

title

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity (English)

1 reference

14 December 2017

0 references

G Poelsler

1

1 reference

14 December 2017

A Berting

2

1 reference

14 December 2017

J Kindermann

3

1 reference

14 December 2017

M Spruth

4

1 reference

14 December 2017

T Hämmerle

5

1 reference

14 December 2017

W Teschner

6

1 reference

14 December 2017

H P Schwarz

7

1 reference

14 December 2017

T R Kreil

8

1 reference

14 December 2017

language of work or name

1 reference

19 December 2007

1 reference

14 December 2017

1 reference

14 December 2017

volume

94

1 reference

14 December 2017

issue

3

1 reference

14 December 2017

page(s)

184-192

1 reference

Reducing the risk of infection from plasma products: specific preventative strategies

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Current strategies to prevent transmission of prions by human plasma derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Solvent-dependent precipitation of prion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Transmissible spongiform encephalopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

The mantra of blood safety: time for a new tune?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

H5N1 influenza virus and the safety of plasma products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Partitioning of TSE infectivity during ethanol fractionation of human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Evaluation of depth filtration to remove prion challenge from an immune globulin preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.2007.01016.X

10.1111/J.1423-0410.2007.01016.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference